On Sept. 22, 2021, Inovio Pharmaceuticals announced that it had received authorization from COFEPRIS, the national health regulatory…
On Sept. 17, 2021, the U.S. Department of Defense in coordination with the Department of Health and Human…
On Aug. 26, 2021, Inovio Pharma announced that it had received regulatory authorization from Brazil’s ANVISA (Agencia Nacional…
On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…
On Aug. 4, 2021, Inovio Pharma announced that the company had dosed the first Phase 2 trial subject…
On Jun. 8, 2021, Inovio Pharma announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals to…
On Jun. 7, 2021, OraSure Technologies announced that it had received Emergency Use Authorization (EUA) from the FDA…
On May 12, 2021, Inovio Pharma announced that its next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies…
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
On Apr. 23, 2021, Inovio Pharma announced that it was planning for a predominantly ex-U.S. Phase 3 trial…
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
On Mar. 30, 2021, OraSure Technologies announced that it had submitted an application to the U.S. Food and…
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
On Jan. 28, 2021, OraSure Technologies announced its OMNIgeneﾮﾷORAL (OME-505) saliva collection device, a product of Ottawa-based subsidiary…
On Jan. 26, 2021, OraSure Technologies announced that Chronomics had selected the OMNIgene-ORAL (OME-505) saliva collection device as…
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
On Jan. 19, 2021, Cue Health announced that its molecular, point-of-care COVID-19 Tests were being distributed to five…
On Jan. 4, 2021, Inovio Pharmaceuticals and Advaccine Biopharmaceuticals announced that they had entered into a collaboration and…
On Dec. 24, 2020, Inovio Pharmaceuticals announced publication of peer-reviewed Phase 1 clinical data from the first cohort…
On Dec. 21, 2020, OraSure Technologies disclosed that the FDA had requested additional information as part of its…
On Dec. 15, 2020, Inovio Pharma announced the company and a team of scientists from The Wistar Institute,…
On Dec. 7, 2020, Inovio Pharmaceuticals announced it had dosed its first subject in a Phase 2 clinical…
On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of…
On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…
On Nov. 3, 2020, OraSure Technologies announced its DNA Genotek subsidiary has received Emergency Use Authorization from the…
On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a…
On Sept. 30, 2020, researchers from the Perelman School of Medicine at the University of Pennsylvania reported results…
On Sept. 28, 2020, INOVIO announced the U.S. Food and Drug Administration (FDA) had notified the company that…
On Sept. 8, 2020, INOVIO announced that Thermo Fisher Scientific, the world leader in serving science, had signed…